Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Gastrointestinal 1

Conditions

Breast Neoplasms 2Vulvar Neoplasms 1Vulvar Diseases 1Vomiting 1Uterine Cervical Dysplasia 1Sarcoma, Alveolar Soft Part 1Papillomavirus Infections 1Nausea 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Inflammatory Breast Neoplasms 1Gynecologic Cancer 1Colonic Neoplasms 1Carcinoma in Situ 1Burkitt Lymphoma 1Breast Neoplasms, Male 1

Interventions

Leucovorin 38Fluorouracil 36Oxaliplatin 34Bevacizumab 34Irinotecan 32Cetuximab 23Capecitabine 18Panitumumab 14IFL protocol 7Folfox protocol 6Celecoxib 6Radiotherapy 5Nivolumab 5Magnetic Resonance Spectroscopy 5Immunohistochemistry 5Gene Expression Profiling 5regorafenib 4pembrolizumab 4dehydroftorafur 4Ramucirumab 4Fluorodeoxyglucose F18 4Floxuridine 4aflibercept 3Surgical Procedures, Operative 3Sorafenib 3Radiosurgery 3Ipilimumab 3Gemcitabine 3Fentanyl 3Drug Therapy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Colonic Neoplasms × Prochlorperazine × Clear all
NCT01851369 2024-05-08

TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
93 enrolled 27 charts
GastrointestinalLymphoid

Colonic Neoplasms, Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡